SCHEMBL1960139

SCHEMBL1960139

COC(=O)c1cnc(N)c(C#C[Si](C)(C)C)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 4/20 0.52
ATM Q13315 2/20 0.43
PDGFRB P09619 7/20 0.43
KDR P35968 7/20 0.43
MAPK1 P28482 2/20 0.40
KDM4E B2RXH2 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PSMD14 O00487 1/20 0.37
IKBKE Q14164 1/20 0.36
TBK1 Q9UHD2 1/20 0.36
ALDH1A1 P00352 2/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GRM5 P41594 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14851276 0.84 ATM (0.44) CSF1RATMPDGFRBKDRMAPK1
SCHEMBL4043719 0.81 CSF1R (0.49) CSF1RATMPDGFRBKDRMAPK1
SCHEMBL1961748 0.80 ATM (0.40) CSF1RATMPDGFRBKDRMAPK1
SCHEMBL4892525 0.78 KDM4E (0.50) ATMMAPK1KDM4EL3MBTL1ALDH1A1
SCHEMBL29204361 0.78 KDM4E (0.54) ATMMAPK1KDM4EL3MBTL1ALDH1A1
SCHEMBL21772930 0.78 CSF1R (0.47) CSF1RATMPDGFRBKDRMAPK1
SCHEMBL16782115 0.77 CSF1R (0.52) CSF1RPDGFRBKDR
SCHEMBL15970711 0.76 KDM4E (0.42) ATMKDM4EL3MBTL1ALDH1A1GLA
SCHEMBL15971127 0.76 NQO2 (0.39) ATMKDM4EL3MBTL1ALDH1A1GLA
SCHEMBL18031226 0.76 KDM4E (0.42) CSF1RATMKDM4EL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102686587-B Azaindole glucokinase activators HOFFMANN LA ROCHE 2015-05-27 CN disclosed
EP-2513103-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 CSF1R 4213/4885ATM 2047/4885PDGFRB 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.